Diadexus, Inc. Stock

DDXSQ

US25245P2056

Pharmaceuticals

Delayed OTC Markets			5-day change	1st Jan Change
- ^USD	-.--%		-.--%	-

17/09/21	Diadexus, Inc. Went Out of Business	CI
08/06/18	Motion for Asset Sale Approved for Diadexus, Inc.	CI

Diadexus, Inc. is a diagnostics company. The Company is engaged in developing and commercializing products that deliver healthcare providers with relevant information to assist in the management of patients throughout the course of cardiac disease. Its capabilities include manufacturing, assay development, Food and Drug Administration (FDA) regulatory clearance, and marketing and selling products. Its commercially-available products consist of two FDA-cleared tests to measure Lp-PLA2: the PLAC Test ELISA Kit (the PLAC ELISA Test) and the PLAC Test for Lp-PLA2 Activity (the PLAC Activity Test). Its other products include proADM; proET-1, which aids in predication of heart failure, and proANP, which aids in predication of heart failure. The Company sells its diagnostic products to laboratories and promotes these products to the laboratories' sales representatives, as well as directly to healthcare providers.

Employees

Sector

Pharmaceuticals

More about the company

Market Cap	49.2K 43.27K 40.92K 37.11K 69.7K 4.72M 70.11K 490K 189K 2.41M 185K 181K 7.74M	P/E 2014	-3.26x	P/E 2015	-1.14x
Enterprise Value	5.29M 4.65M 4.4M 3.99M 7.49M 508M 7.54M 52.68M 20.35M 259M 19.86M 19.43M 833M	EV / Sales 2014	1.05x	EV / Sales 2015	0.77x
Free-Float	100%	Yield 2014 *	-	Yield 2015	-

17/09/21	Diadexus, Inc. Went Out of Business	CI
08/06/18	Motion for Asset Sale Approved for Diadexus, Inc.	CI
09/05/18	Motion for Asset Sale Filed by Diadexus, Inc.	CI
01/08/16	Diazyme Laboratories, Inc. completed the acquisition of operational assets from Diadexus, Inc. (OTCPK:DDXS.Q).	CI
29/07/16	Motion for Asset Sale Approved for Diadexus, Inc.	CI
29/07/16	General Atomics Corp. entered into purchase agreement to acquire operational assets from Diadexus, Inc. (OTCPK:DDXS.Q) for $4.8 million.	CI
20/07/16	Cleveland HeartLab, Inc. cancelled the acquisition of operational assets from Diadexus, Inc. (OTCPK:DDXS.Q).	CI
07/07/16	Motion for Asset Sale Filed by Diadexus, Inc.	CI
07/07/16	Cleveland HeartLab, Inc. agreed to acquire operational assets from Diadexus, Inc. (OTCPK:DDXS.Q) for $7 million.	CI
13/06/16	Diadexus, Inc. Filed for Bankruptcy	CI
10/06/16	Diadexus, Inc. Announces Resignation of Leone Patterson as Chief Financial Office	CI
23/05/16	Diadexus, Sonic Healthcare USA Sign National Agreement for PLAC Activity Test	CI
30/04/16	Diadexus, Inc. Reports Unaudited Earnings Results for the First Quarter Ended March 31, 2016	CI

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
DIADEXUS, INC.	-.--%	-.--%	-	-	410
SAREPTA THERAPEUTICS, INC.	+0.32%	-7.60%	-1.12%	-84.94%	1.97B
ULTRAGENYX PHARMACEUTICAL INC.	-0.86%	-2.05%	-52.73%	-59.20%	1.43B
BIONOTE, INC.	+0.32%	+0.11%	-20.21%	-3.12%	345M
DK LIFE SCIENCE CO., LTD.	+22.32%	+47.63%	-15.64%	-	65.97M
Average	+4.41%	+8.10%	-22.42%	-49.09%	761.71M
Weighted average by Cap.	+0.21%	-2.90%	-22.41%	-67.59%

	2014	2015
Net sales	26.11M 22.97M 21.72M 19.7M 36.99M 2.51B 37.21M 260M 100M 1.28B 98.03M 95.91M 4.11B	17.88M 15.73M 14.87M 13.49M 25.34M 1.72B 25.48M 178M 68.78M 876M 67.14M 65.69M 2.81B
Net income	-8.47M -7.45M -7.04M -6.39M -11.99M -813M -12.06M -84.31M -32.56M -415M -31.79M -31.1M -1.33B	-7.17M -6.3M -5.96M -5.41M -10.15M -688M -10.21M -71.36M -27.56M -351M -26.9M -26.32M -1.13B
Net Debt	-198K -174K -165K -149K -281K -19.01M -282K -1.97M -761K -9.7M -743K -727K -31.17M	5.24M 4.61M 4.36M 3.95M 7.42M 503M 7.47M 52.19M 20.16M 257M 19.68M 19.25M 825M

Diadexus, Inc. Stock

Stocks

DDXSQ

US25245P2056

Pharmaceuticals

Valuation: Diadexus, Inc.

Latest news: Diadexus, Inc.

Diagnostic & Testing Substances Manufacturers

Financials

Company Profile